The short answer
Ginkgo warrants a precautionary review with celecoxib, but the size of any added bleeding risk is uncertain. The available study used aspirin, and cannot establish what happens with celecoxib.
What this answer covers
Oral Ginkgo biloba leaf preparations. Defined dry leaf extract and powdered leaf have separate monograph provisions; seeds and unrelated extracts are excluded.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- celecoxib
What the studies can tell us
In 50 healthy men, adding the standardized ginkgo extract EGb 761 to aspirin for seven days did not further prolong bleeding time. This short study measured laboratory responses, not long-term celecoxib bleeding outcomes. It cannot prove this combination safe.
Check the exact product
The EMA monograph cautions about ginkgo leaf extracts with aspirin and other NSAIDs. Celecoxib belongs to the NSAID group, but its label reports no platelet inhibition in the tested regimens. The precaution supports discussing use, without assuming that celecoxib behaves like aspirin.
Review your bleeding risks
Celecoxib itself can cause serious stomach or intestinal bleeding. Tell your prescriber about previous ulcers or bleeding and about aspirin, anticoagulants, steroids and other pain medicines. Share all supplement labels. The available sources do not establish an hours-apart schedule that prevents this possible interaction.
When to get medical help
Stop celecoxib and seek medical help promptly for vomiting blood, black or bloody stools, or faintness with possible bleeding. Report new persistent stomach pain or unusual bleeding to your clinician. These warning signs matter even when the added effect of the supplement is uncertain.
Evidence and practical considerations
Side effects & toxicity
The inspected evidence is insufficient to establish that ginkgo increases bleeding when combined with celecoxib.
- Exact scope
- Oral Ginkgo biloba leaf preparations. Defined dry leaf extract and powdered leaf have separate monograph provisions; seeds and unrelated extracts are excluded. with Celecoxib, RxCUI 140587 IN, oral treatment.
- Medication form and route
- Oral
What remains uncertain
- No inspected clinical co-use study establishes this exact interaction or its frequency. Absence of such evidence does not prove safety.
Factors that may matter: Exact product and dose; Kidney function; Other medicines; Prior gastrointestinal bleeding or ulcers.
Read the supporting source summaries
Source 1: Regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral celecoxib.
Celecoxib can cause serious gastrointestinal bleeding. The label also warns of renal toxicity and hyperkalemia. Healthy-volunteer testing found no reduction of platelet aggregation or increase in bleeding time at the tested celecoxib regimens.
How this applies: Exact celecoxib identity, baseline risks and clinical counseling; no direct botanical co-use outcome.
Baseline adverse effects do not prove an added botanical interaction. NSAID wording must not be converted into an aspirin-like platelet effect for celecoxib.
Source 2: primary randomized crossover trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 50 healthy men aged 20-44 years, randomized to two treatment sequences.
Aspirin prolonged bleeding time, but adding EGb 761 did not further prolong it: mean post-treatment values 6.2 versus 6.3 minutes; ratio 1.01, 90% CI 0.86-1.19. Other measured coagulation and platelet effects were similar.
How this applies: Aspirin co-use study of EGb 761, not celecoxib. Its null surrogate result cannot establish safety or harm of this exact pair.
Abstract only, seven-day exposure, healthy young men and surrogate tests. Authors extended reassurance to elderly people in their conclusion, but this population was not studied; no such extrapolation is adopted.
Source 3: official regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Adults using the defined ginkgo leaf dry extract; separate provisions cover powdered leaf.
Warns that effects of concomitant antiplatelet medicines, including aspirin and other NSAIDs, may be influenced. Calls for medical consultation in specified bleeding-risk settings.
How this applies: Supports cautious review of defined ginkgo leaf extracts in an NSAID user, with explicit limits on the class bridge and preparation. Does not prove an increased celecoxib bleeding rate or an hours-apart rule.
Precautionary class wording, not a celecoxib trial. Celecoxib did not inhibit platelets in its label studies, so an aspirin-like mechanism must not be assumed. The dry-extract and powdered-leaf columns differ.
Research assessment: · Open full citations ↗
Side effects & toxicity
A review of the exact ginkgo leaf extract is reasonable before concurrent celecoxib use, based on the EMA NSAID precaution and celecoxib baseline gastrointestinal risk.
- Exact scope
- Oral Ginkgo biloba leaf preparations. Defined dry leaf extract and powdered leaf have separate monograph provisions; seeds and unrelated extracts are excluded. with Celecoxib, RxCUI 140587 IN, oral treatment.
- Medication form and route
- Oral
What remains uncertain
- This is a precautionary class application. Celecoxib is not assumed to inhibit platelets like aspirin; the exact combination and risk magnitude were not studied.
Factors that may matter: Exact product and dose; Kidney function; Other medicines; Prior gastrointestinal bleeding or ulcers.
Read the supporting source summaries
Source 1: official regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Adults using the defined ginkgo leaf dry extract; separate provisions cover powdered leaf.
Warns that effects of concomitant antiplatelet medicines, including aspirin and other NSAIDs, may be influenced. Calls for medical consultation in specified bleeding-risk settings.
How this applies: Supports cautious review of defined ginkgo leaf extracts in an NSAID user, with explicit limits on the class bridge and preparation. Does not prove an increased celecoxib bleeding rate or an hours-apart rule.
Precautionary class wording, not a celecoxib trial. Celecoxib did not inhibit platelets in its label studies, so an aspirin-like mechanism must not be assumed. The dry-extract and powdered-leaf columns differ.
Source 2: Regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral celecoxib.
Celecoxib can cause serious gastrointestinal bleeding. The label also warns of renal toxicity and hyperkalemia. Healthy-volunteer testing found no reduction of platelet aggregation or increase in bleeding time at the tested celecoxib regimens.
How this applies: Exact celecoxib identity, baseline risks and clinical counseling; no direct botanical co-use outcome.
Baseline adverse effects do not prove an added botanical interaction. NSAID wording must not be converted into an aspirin-like platelet effect for celecoxib.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: aa2590238189509a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.